Literature DB >> 18486055

Pyrazinamide.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18486055     DOI： 10.1016/S1472-9792(08)70021-0

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


× No keyword cloud information.
  10 in total

1.  Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels.

Authors:  Ping Lu; Anna C Haagsma; Hoang Pham; Janneke J Maaskant; Selena Mol; Holger Lill; Dirk Bald
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

2.  Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish Larvae.

Authors:  Yun Zhang; Kechun Liu; Hozeifa M Hassan; Hongli Guo; Pingping Ding; Liwen Han; Qiuxia He; Weiyun Chen; Chung-Der Hsiao; Luyong Zhang; Zhenzhou Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Analysis of influencing factors on the plasma concentration of first-line anti-tuberculosis drugs-a single-center retrospective cohort study.

Authors:  Guanren Zhao; Ming Chen; Lijun Sun; Na Xi
Journal:  Ann Transl Med       Date:  2022-04

4.  Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.

Authors:  Sivaranjani Namasivayam; Mamoudou Maiga; Wuxing Yuan; Vishal Thovarai; Diego L Costa; Lara R Mittereder; Matthew F Wipperman; Michael S Glickman; Amiran Dzutsev; Giorgio Trinchieri; Alan Sher
Journal:  Microbiome       Date:  2017-07-07       Impact factor: 14.650

5.  The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography.

Authors:  Zhuo Zhang; Alvaro A Ordonez; Peter Smith-Jones; Hui Wang; Kayla R Gogarty; Fereidoon Daryaee; Lauren E Bambarger; Yong S Chang; Sanjay K Jain; Peter J Tonge
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

6.  Multi-Methodological Quantitative Taste Assessment of Anti-Tuberculosis Drugs to Support the Development of Palatable Paediatric Dosage Forms.

Authors:  Alison V Keating; Jessica Soto; Claire Forbes; Min Zhao; Duncan Q M Craig; Catherine Tuleu
Journal:  Pharmaceutics       Date:  2020-04-17       Impact factor: 6.321

7.  Development of a novel anti-tuberculosis nanodelivery formulation using magnesium layered hydroxide as the nanocarrier and pyrazinamide as a model drug.

Authors:  Bullo Saifullah; Palanisamy Arulselvan; Sharida Fakurazi; Thomas J Webster; Naeemullah Bullo; Mohd Zobir Hussein; Mohamed E El Zowalaty
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

8.  Synthesis and Tuberculostatic Activity Evaluation of Novel Benzazoles with Alkyl, Cycloalkyl or Pyridine Moiety.

Authors:  Malwina Krause; Henryk Foks; Ewa Augustynowicz-Kopeć; Agnieszka Napiórkowska; Małgorzata Szczesio; Katarzyna Gobis
Journal:  Molecules       Date:  2018-04-23       Impact factor: 4.411

Review 9.  The Microbiome and Tuberculosis: Early Evidence for Cross Talk.

Authors:  Sivaranjani Namasivayam; Alan Sher; Michael S Glickman; Matthew F Wipperman
Journal:  MBio       Date:  2018-09-18       Impact factor: 7.867

10.  A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting.

Authors:  Söenke Andres; Matthias I Gröschel; Doris Hillemann; Matthias Merker; Stefan Niemann; Katharina Kranzer
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.